The Evolving Treatment Landscape in CLL: Updates from ASH 2021

Anthony Perissinotti, PharmD, BCOP, provides an overview of the available treatment options in chronic lymphocytic leukemia, highlighting the role of first-generation BTK inhibitors.

Kirollos Hanna, PharmD, BCPS, BCOP, discusses clinical trial data for second-generation BTK inhibitors for chronic lymphocytic leukemia.

Dr Kirollos Hanna details clinical trial data on the use of zanubrutinib in treating chronic lymphocytic leukemia.

Dr Anthony Perissinotti explains the new formulation of acalabrutinib for chronic lymphocytic leukemia presented at ASH 2021.

A hematology expert describes data from clinical trials on venetoclax-based therapies for chronic lymphocytic leukemia.

Key opinion leaders discuss data from the MURANO trial on a fixed-duration therapy for relapsed/refractory chronic lymphocytic leukemia.

Kirollos Hanna, PharmD, BCPS, BCOP, reviews the use of anti-CD20 monoclonal antibodies for treating chronic lymphocytic leukemia.

Anthony Perissinotti, PharmD, BCOP, explains potential scenarios requiring anti-CD20 monoclonal antibodies as a therapy for chronic lymphocytic leukemia.

Chronic lymphocytic leukemia experts debate how to prevent or reduce the risk of tumor lysis in patients.

Anthony Perissinotti and Kirollos Hanna discuss considerations for selecting treatment regimens in chronic lymphocytic leukemia.

Dr Anthony Perissinotti details an effective new therapy on the horizon in chronic lymphocytic leukemia.

Experts discuss the potential future use of CAR T-cell therapy and bispecific therapeutics for chronic lymphocytic leukemia based on data presented at ASH 2021.

Drs Anthony Perissinotti and Kirollos Hanna provide some important considerations for pharmacists in treating chronic lymphocytic leukemia.